Nektar Sells Rezvoglar Rights for $10M Upfront
Ticker: NKTR · Form: 8-K · Filed: Mar 4, 2024 · CIK: 906709
Sentiment: neutral
Topics: divestiture, asset-sale, pipeline-focus
Related Tickers: NKTR
TL;DR
Nektar cashes out $10M for rezvoglar rights, focusing on pipeline.
AI Summary
Nektar Therapeutics announced on March 4, 2024, that it has entered into a definitive agreement to sell its U.S. commercial rights for the drug rezvoglar to a third party for an upfront payment of $10 million. The agreement also includes potential milestone payments and royalties. This transaction is part of Nektar's strategy to focus on its pipeline of novel drug candidates.
Why It Matters
This divestiture allows Nektar to streamline its operations and focus resources on developing its pipeline, potentially accelerating the path to market for new therapies.
Risk Assessment
Risk Level: medium — The sale of commercial rights indicates a strategic shift and potential financial pressures, while the success of the remaining pipeline is not guaranteed.
Key Numbers
- $10.0M — Upfront Payment (Received for U.S. commercial rights to rezvoglar)
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- rezvoglar (drug) — Commercial rights sold
- $10 million (dollar_amount) — Upfront payment for rezvoglar rights
- March 4, 2024 (date) — Date of definitive agreement
FAQ
What is the specific nature of the definitive agreement Nektar Therapeutics entered into?
Nektar Therapeutics entered into a definitive agreement to sell its U.S. commercial rights for the drug rezvoglar to a third party.
What is the upfront payment Nektar Therapeutics will receive for the rezvoglar rights?
Nektar Therapeutics will receive an upfront payment of $10 million.
Are there any additional payments beyond the upfront amount for the rezvoglar rights?
Yes, the agreement includes potential milestone payments and royalties in addition to the upfront payment.
What is the stated strategic reason for this divestiture?
The transaction is part of Nektar's strategy to focus on its pipeline of novel drug candidates.
When was the date of the report for this event?
The date of the report is March 4, 2024.
Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-03-04 16:20:46
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
- $15 million — rest in the royalties in exchange for a $15 million cash payment from entities managed by H
Filing Documents
- ea0201095-8k_nektarther.htm (8-K) — 25KB
- ea0201095ex99-1_nektarther.htm (EX-99.1) — 77KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-019557.txt ( ) — 284KB
- nktr-20240304.xsd (EX-101.SCH) — 3KB
- nktr-20240304_lab.xml (EX-101.LAB) — 33KB
- nktr-20240304_pre.xml (EX-101.PRE) — 22KB
- ea0201095-8k_nektarther_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On March 4, 2024, Nektar Therapeutics ("Nektar") and entities managed by Healthcare Royalty entered into an Amendment No 1. (the "Amendment") to that certain Purchase and Sale Agreement, dated as of December 16, 2020, as more fully described in Nektar's Current Report on Form 8-K filed on December 22, 2020 (the "Purchase Agreement"). The terms of the Purchase Agreement provided for Nektar to receive a reversionary interest in the royalties if certain aggregate thresholds were met. The Amendment removes Nektar's revisionary interest in the royalties in exchange for a $15 million cash payment from entities managed by Healthcare Royalty to Nektar. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, a copy of which will be filed as an exhibit to Nektar's Quarterly Report on Form 10-Q for the period ended March 31, 2024.
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On March 4, 2024, Nektar issued a press release (the "Press Release") announcing its financial results for the quarter and year ended December 31, 2023. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: March 4, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2